AI assistant
AVADEL PHARMACEUTICALS PLC — Director's Dealing 2024
May 3, 2024
31920_dirs_2024-05-03_ca936d7d-fbc5-4139-a9d7-acaed7385b2a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2024-04-30
Reporting Person: Seurer Jerad G. (Gen. Counsel & Corp. Secretary)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Ordinary Shares | 8795 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $9.67 | 2027-11-07 | Ordinary Shares (25000) | Direct | |
| Stock Option (Right to Buy) | $7.55 | 2030-01-02 | Ordinary Shares (30000) | Direct | |
| Stock Option (Right to Buy) | $6.79 | 2030-12-08 | Ordinary Shares (80000) | Direct | |
| Stock Option (Right to Buy) | $8.20 | 2031-12-07 | Ordinary Shares (47500) | Direct | |
| Stock Option (Right to Buy) | $4.69 | 2032-08-04 | Ordinary Shares (100000) | Direct | |
| Stock Option (Right to Buy) | $13.57 | 2034-02-20 | Ordinary Shares (125000) | Direct |
Footnotes
F1: Options fully vested and exercisable.
F2: Options become exercisable as to 20,000 ordinary shares on each of the first four anniversaries after the 12/8/2020 grant date.
F3: Options become exercisable as to 11,875 ordinary shares on each of the first four anniversaries after the 12/7/2021 grant date.
F4: Options become exercisable as to 50,000 ordinary shares on each of 6/1/2023 and 6/1/2024.
F5: Options become exercisable as to 31,250 ordinary shares on each of the first four anniversaries after the 2/20/2024 grant date.